Effect of Xuesaitong as an Adjuvant Therapy for Primary Sjögren Syndrome

HAN Dan; CHANG Qiongjie; ZHAO Man; WANG Jing; LIU Zhidui; CHEN Yunzhuan

doi:10.3969/j.issn.1004-437X.2026.02.007

Abstract：Objective To explore the effects of Xuesaitong adjuvant therapy on immunoglobulin(Ig)and inflammatory cytokines in patients with primary Sjögren syndrome.Methods A total of 96 patients with primary Sjögren syndrome treated in Zhengzhou People's Hospital from January to September 2024 were divided into observation group(48 cases)and control group(48 cases)by random number table method.Both groups were treated with methylprednisolone tablets and hydroxychloroquine sulfate tablets,and the observation group was treated with Xuesaitong for injection.Both groups were treated for 14 days.The EULAR Sjögren syndrome patient reported index(ESSPRI)was used to determine the severity of the two groups of patients before and after treatment.Serum Ig indexes of IgA,IgG and IgM and serum inflammatory cytokines of C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interferon-γ(IFN-γ)were detected.The adverse reactions of the two groups were recorded.Results After treatment,the scores of ESSPRI and all symptoms were significantly decreased in both groups,and the scores in the observation group were significantly lower(P＜0.05).After treatment,serum Ig indexes(IgA,IgG and IgM)and inflammatory cytokines(CRP,TNF-α and IFN-γ)were significantly decreased in both groups,and the levels of Ig indexes and inflammatory cytokines in the observation group were significantly lower(P＜0.05).There was no significant difference in adverse reactions between the two groups(P＞0.05).Conclusion The combined treatment of Xuesaitong with methylprednisolone and hydroxychloroquine sulfate could promote the elimination of clinical symptoms and the reduction of the disease severity in patients with primary Sjögren syndrome,regulate the immune function of the body.The drug safety of this treatment scheme was high.